Detection of erbB-2 amplifications in tumors and sera from esophageal carcinoma patients.
We used TaqMan PCR to detect quantitative anomalies of tumor markers in both tumor and serum DNA from esophageal cancer patients. We demonstrated the potential of this methodology by detecting erbB-2 amplifications in a plurality of esophageal tumor samples. These amplifications were corroborated by Southern blots. We then showed the potential of this methodology to detect quantitative anomalies of erbB-2 in serum DNA from individuals with a corresponding amplification in the tumor. The capability of TaqMan PCR to detect abnormalities in serum of esophageal cancer patients creates an opportunity to diagnose esophageal cancer and to monitor the outcome of treatment with a blood test.
Chiang
P W
PW
Department of Pediatrics, University of Michigan Medical Center, Ann Arbor 48109-0650, USA. pwchiang@umich.edu
Beer
D G
DG
Wei
W L
WL
Orringer
M B
MB
Kurnit
D M
DM
D000230:Adenocarcinoma / Q000097:blood / Q000235:genetics*; D015139:Blotting, Southern; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000235:genetics; D004273:DNA, Neoplasm / Q000097:blood*; D004938:Esophageal Neoplasms / Q000097:blood / Q000235:genetics*; D005784:Gene Amplification; D018628:Gene Dosage; D018734:Genes, erbB-2 / Q000235:genetics*; D006801:Humans; D016133:Polymerase Chain Reaction; D019707:Receptors, Chemokine / Q000235:genetics; D016159:Tumor Suppressor Protein p53 / Q000235:genetics
C102741:CMKLR1 protein, human; D019941:Cyclin-Dependent Kinase Inhibitor p16; D004273:DNA, Neoplasm; D019707:Receptors, Chemokine; D016159:Tumor Suppressor Protein p53